Cargando…
OTSSP167 Abrogates Mitotic Checkpoint through Inhibiting Multiple Mitotic Kinases
OTSSP167 was recently characterized as a potent inhibitor for maternal embryonic leucine zipper kinase (MELK) and is currently tested in Phase I clinical trials for solid tumors that have not responded to other treatment. Here we report that OTSSP167 abrogates the mitotic checkpoint at concentration...
Autores principales: | Ji, Wenbin, Arnst, Christopher, Tipton, Aaron R., Bekier, Michael E., Taylor, William R., Yen, Tim J., Liu, Song-Tao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833387/ https://www.ncbi.nlm.nih.gov/pubmed/27082996 http://dx.doi.org/10.1371/journal.pone.0153518 |
Ejemplares similares
-
Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia
por: Bridges, Cory Seth, et al.
Publicado: (2022) -
Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
por: Muller, Joséphine, et al.
Publicado: (2018) -
Analysis of the role of GSK3 in the mitotic checkpoint
por: Rashid, M. S., et al.
Publicado: (2018) -
Mitotic checkpoints, MUGs and kinetochores
por: Brinkley, Bill R.
Publicado: (2013) -
SUN-337 Anti-tumorigenic Effects Of The Maternal Leucine Zipper Kinase (MELK) Inhibitor, OTSSP167, In Pre-clinical In Vivo Models Of Adrenocortical Carcinomas (ACC)
por: KAR, ADWITIYA, et al.
Publicado: (2019)